# Lunai (LNAI) — News

LNAI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lnai/news

## Recent headlines

- [Trading halted: (LNAI) Due to limit-up limit-down trading pause](https://www.ainvest.com/news/trading-halted-lnai-due-limit-limit-trading-pause-2610) — AInvest Wire, Oct 9, 2026
  Trading in the stock of LNAI has been temporarily suspended due to a limit-up limit-down trading pause, a regulatory mechanism designed to prevent excessive volatility and provide market participants with time to reassess positions. The pause was triggered as the stock’s price moved beyond…
- [OpenAI: Oct release of GPT-6 Sol & GPT-6 Luna assessed as high capability in cybersecurity, biological, chemical domains under preparedness framework](https://www.ainvest.com/news/openai-oct-release-gpt-6-sol-gpt-6-luna-assessed-high-capability-cybersecurity-biological-chemical-domains-preparedness-framework-2610) — AInvest Wire, Oct 7, 2026
  OpenAI has introduced two new models, GPT-6 Sol and GPT-6 Luna, as part of its GPT-6 series, with a focus on cost efficiency and performance in specialized domains such as cybersecurity, biology, and chemistry. These models are positioned as lower-cost alternatives to the higher-tier GPT-6 Astra,…
- [Light AI - Will not advance toward FDA submission until readiness established](https://www.ainvest.com/news/light-ai-advance-fda-submission-readiness-established-2610) — AInvest Wire, Oct 3, 2026
  Light AI Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF) has indicated that it will not pursue a U.S. Food and Drug Administration (FDA) submission for its investigational Software as a Medical Device (SaMD) product, QuickScan™ Strep A, until it has fully established readiness for regulatory review.…
- [Lunai Bioworks Inc: Anticipates reporting a net loss for the fiscal year ended June 30, 2026 of about $3.2 million](https://www.ainvest.com/news/lunai-bioworks-anticipates-reporting-net-loss-fiscal-year-ended-june-30-2026-3-2-million-2609) — AInvest Wire, Sep 29, 2026
- [Lunai Bioworks Inc: Files for non timely 10-K with U.S. SEC](https://www.ainvest.com/news/lunai-bioworks-files-timely-10-sec-2609) — AInvest Wire, Sep 29, 2026
  Lunai Bioworks Inc. (NASDAQ: LNAI) has continued to face regulatory scrutiny due to its failure to file required financial reports with the U.S. Securities and Exchange Commission (SEC). The company remains non-compliant with Nasdaq Listing Rule 5250(c)(1), which mandates timely submission of all…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).